DCT Blog post

Understanding vendor management challenges in Decentralized Clinical Trials (DCT, aka Hybrid and Virtual Trials)

The purported benefits of decentralized clinical trials (DCT) include accelerated enrollment, reduced patient burden and improved retention rates, among other efficiencies. Incorporating virtual elements into the traditional trial model requires a clear vision for the technologies, platforms and other “site-less” elements that support these efforts; however, the potential challenges of …

ican peds

Protecting the safety of pediatric clinical trial participants during a pandemic

As clinical trials worldwide are facing unprecedented challenges with the COVID-19 pandemic, the experts working at the regulatory bodies and pharmaceutical companies and staff working at contract research organizations (CRO), such as Covance, have a focus to maintain patient safety as a top priority.  Almost overnight we saw many hospitals …

covid-19 covance labcorp diagnostics drug development

Covance and LabCorp deliver unmatched COVID-19 diagnostic and therapeutic applications

We’re in this together: How Covance and LabCorp are delivering unmatched acceleration of COVID-19 diagnostic and therapeutic applications Accelerating much needed COVID-19 testing, vaccines and treatment options across the world can’t be done alone. We’re in this together and ready to apply our unique combination of solutions that blend Covance …

Ulcerative Colitis Recruitment

Incorporating the patient voice to improve ulcerative colitis recruitment

The exact cause of ulcerative colitis (UC) is still unknown, but approximately 700,000 people in the United States suffer from this chronic, life-long disease that causes inflammation in the large intestine. A wide range of treatment options are available, but drug development sponsors are seeking additional ways to control inflammation, …

RA Biosimilar Recruitment

Is a different recruitment strategy required to enroll RA biosimilar studies? How to succeed despite increasing volume of RA biosimilar development programs

Introduction Although a range of regulatory definitions exist, a biosimilar drug is generally defined as \a biological compound that is highly similar to the reference drug, with no clinically meaningful differences in safety, purity and potency.1,2 In addition, biosimilars can be characterized as reducing healthcare costs while maintaining clinical efficacy …

Closing the knowledge gap with Real-World Evidence (RWE) studies: the importance of starting early

Successfully demonstrating product safety and efficacy in a randomized clinical trial is a monumental event, but it doesn’t always translate to market access and uptake one it’s launched. Since clinical trials are limited to a controlled sub-set of patients, observations recorded in the clinical trial setting can vary from what …

RA Biosimilar Recruitment

RA biosimilar studies recruitment strategy? How to succeed despite increasing volume of RA biosimilar development programs

Introduction Although a range of regulatory definitions exist, a biosimilar drug is generally defined as a biological compound that is highly similar to the reference drug, with no clinically meaningful differences in safety, purity and potency.1,2 In addition, biosimilars can be characterized as reducing healthcare costs while maintaining clinical efficacy …

Customizing real-world evidence (RWE) study designs: a new framework tool that incorporates elements of virtual study design

While assisting clients with their clinical development plans, and post-marketing studies, our team is witnessing a trend in designing RWE studies with both traditional and virtual elements. With growing interest in hybrid designs, Covance is exploring how we can help our clients incorporate their study objectives while evaluating a range …